Evidence Explorer · MS-N272 · Supportive physical care · Appraised November 8, 2026
A 50-participant trial reported faster late recovery of skin thickness and radiodermatitis grades with pulsed electromagnetic field therapy added to standard skin care, but the peak four-week clinical-grade comparison was not significant and a published letter raised methodological cautions.
Evidence at a glance
- Population: 50 women aged 35–55 after lumpectomy receiving hypofractionated whole-breast irradiation.
- Intervention: pulsed electromagnetic field therapy plus standard skin care.
- Comparator: standard skin care alone.
- Key result: grade 3 reactions at week 4 were 12% versus 36% (P=.150); later week-6 and week-8 grade distributions favored treatment.
- Evidence label: preliminary single-center evidence with timing and methods concerns.
What was studied
Skin thickness and RTOG grades were measured over eight weeks. At week 8, 52% of the PEMF group versus 8% of controls had returned to grade 0. The trial was prospectively registered as NCT06003764.
A linked 2026 correspondence urged caution about interpretation. The study was small, single-center and not a substitute for established radiotherapy skin-care protocols.
What this evidence cannot establish
The nonsignificant four-week clinical comparison, multiple time points and limited age and treatment range weaken certainty. The trial does not establish prevention of treatment interruption, chronic fibrosis, wound complications or cancer-control benefit.
Safety and practical context
Electromagnetic devices require oncology and device-safety review, particularly with pacemakers, implanted stimulators or other electronic devices. Radiotherapy skin reactions can worsen quickly; moist desquamation, infection, severe pain or treatment interruption needs direct radiation-team management.
Questions for the care team
- Is this device compatible with all implanted hardware and the radiotherapy plan?
- Which prespecified outcome matters: peak dermatitis, recovery time, pain or treatment interruption?
- What standard skin care will continue, and what findings require stopping the device?
Sources and identifiers
- Randomized trial — PMID 41642361
- Published critical correspondence — PMID 42105093
Funding and conflicts: The authors declared no competing interests. Funding details were not verified in the checked full text.
Source access and dates: Original PubMed records and available full texts were checked November 8, 2026. Last literature search November 8, 2026.
Educational evidence summary, not individualized medical advice. Supportive-care outcomes do not demonstrate tumor response, recurrence prevention or longer survival.
